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SURGERY FOR ACQUIRED 
HEART DISEASE 
LATE ENDOTHELIAL 
FUNCTION OF FREE AND 
PEDICLED INTERNAL 
MAMMARY ARTERY GRAFTS 
The internal mammary artery has greater long-term patency than the 
saphenous vein when used for coronary bypass grafting. Therefore, bilat- 
eral use of the internal mammary artery for grafting with the right internal 
mammary artery used as a "free" graft may result in improved graft 
survival. The study objectives were to compare the endothelial-dependent 
and -independent vasodilatory response in free and pedicled internal 
mammary artery grafts in patients who had previously undergone coronary 
surgery. Free (group 1, n = 8) and pedicled (group 2, n = 7) internal 
mammary artery grafts were studied by comparing the response to selective 
infusion of the endothelial-dependent vasodilator substance P (1.4 up to 
22.4 pmol/min in doubling dose increments) followed by isosorbide dini- 
trate (2 mg over 2 minutes), in patients undergoing coronary angiography, 
1 month to 6 years after coronary surgery. Maximal dilatory response to 
substance P was 8.7% - 1.8% in pedicled grafts compared with 8.8% +-- 2.3% 
in free grafts (p = not significant), with e dose response for both groups 
being similar. Infusion of isosorbide dinitrate produced only minimal 
further dilatation in both groups. No significant difference was found in 
endothelium-dependent and -independent vasodilatory response between 
free and pedicled internal mammary artery grafts, suggesting that the use 
of the free right internal mammary artery and other arterial grafts may 
enhance graft survival. (J THORAC CARDIOVASC SURG 1995;110:453-62) 
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T he internal mammary artery (IMA) has been shown to have greater long-term patency for 
coronary artery bypass grafting when compared with 
the saphenous vein graft. 1'2 The vasodilator and 
antithrombofic properties of the vascular endothe- 
lium, which ]have been shown to be superior in the 
IMA compared with the saphenous vein grafts, 3
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may be responsible for this greater long-term pa- 
tency. The endothelium has been shown to modu- 
late underlying vascular smooth muscle by the re- 
lease of endothelium-derived r laxing factor, 4which 
also reduces intraluminal platelet adhesion 5 and 
has potent antiaggregatory properties. 6 These anti- 
thrombotic properties may prevent he development 
of atherosclerosis, which develops with much 
greater frequency in saphenous vein grafts. 
For this reason, interest has increased in the use 
of arterial conduits for coronary artery bypass graft- 
ing. 7 Bilateral use of the IMA for grafting has 
theoretical advantages over saphenous vein grafts) 
One of the techniques is to use the right IMA as a 
"free" graft. The IMA is transected near the origin 
of the subclavian artery, with the proximal end being 
anastomosed to the aorta and the distal end to the 
coronary artery. 9 The advantages of this technique 
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include the potential for grafting any branch of the 
coronary system and the possibility of using two or 
three segments of the same internal mammary ves- 
sel for grafting different vessels without resorting to 
sequential anastomosis. In addition, the technique 
can be used in patients with occlusive disease of the 
subclavian artery or accidental injury of the proxi- 
mal IMA during dissection. Endothelial function of 
the IMA has been examined in vitro, 1° but endothe- 
lial-dependent and endothelial-independent vasodi- 
latory abilities of the free graft have not been 
assessed in human subjects. Use of the free graft 
results in the denervation of the IMA with loss of 
the vasa vasorum and lymphatics, which may affect 
arterial vasodilatory ability, particularly in relation 
to flow mediated ilatation 11 as a result of increased 
myocardial demand. This study was carried out to 
examine and compare the endothelium-dependent 
and endothelial-independent vasodilatory response 
of flee right and pedicled left IMA grafts in human 
subjects who had undergone coronary artery bypass 
grafting. 
Substance P is an 11 amino acid vasodilator 
neuropeptide. It is found in the peripheral nervous 
system in sensory neurons, 12 the vagus, 13 and some 
sympathetic ganglia. 14 It is a potent vasodilator in 
human beings, causing vasodilatation i  the forearm 
when infused into the brachial artery is and dilating 
epicardial coronary arteries when infused into the 
coronary circulationJ 6 The vasodilator action of 
substance P has been shown to be endothelium 
dependent in most species 17 including man, is' 19 
and its action in human coronary rings is inhibited 
by the nitric oxide synthesis inhibitor L-N 6- 
monomethyl-arginine, 2° which is a specific inhib- 
itor of nitric oxide from its precursor L-arginine. 
These findings suggest that substance P causes 
vasodilatation through the release of nitric oxide 
from the endothelium and, unlike acetylcholine, 21 
has no vasoconstrictor action at higher doses and 
in coronary artery disease, making it suitable for 
the assessment of graft endothelial function in the 
present study population. 
Methods 
A total of 15 patients were studied. Of these, seven had 
pedicled left IMA grafts and eight had free right IMA 
grafts in addition to left IMA grafts. In addition to 
receiving these grafts, all patients also had venous grafts, 
technical details of proximal and distal anastomoses are 
given in Table I, which also includes time of operation, 
location of coronary bypass grafts, and patency at angiog- 
raphy. In the patients with free IMA grafts, the free graft 
was used for the study. All IMA grafts that were studied 
were found to be patent with no angiographic evidence of 
atherosclerotic disease. 
Substance P infusion was carried out after left ventricu- 
lography and selective coronary angiography. Coronary ar- 
tefiography was carried out with the Judldns technique. A
baseline angiogram with iohexol radiopaque agent (Om- 
nipaque 350) was performed inthe projection best displaying 
the pedicled or flee IMA graft as determined previously 
from the diagnostic films. This position was not altered 
throughout the course of the study. A high resolution 12.7 
cm image intensifier (Optimus M200; Phillips Electronics, 
Sheldon, Conn.) was used. After a control angiogram, saline 
solution was infused at 1 ml/min for 2 minutes. This vehicle 
infusion was carried out before the infusions of substance P 
in all patients tudied and was followed by an angiogram. 
Increasing concentrations ofsubstance P were then infused 
at 1 ml/min for 2 minutes with a starting dose of 1.4 
pmol/min and increasing in doubling increments up to a 
maximum dose of 22.4 pmol/min. Immediately after each 
infusion a coronary angiogram was performed. On comple- 
tion of the substance P infusions, isosorbide dinitrate was 
infused at 1 rag/rain for 2 minutes after which a final 
angiogram was taken. 
Informed written consent was obtained from each pa- 
tient, and the study was approved by the District Ethical 
Committee of Harefield Hospital. 
Quantitative angiographic analysis. Coronary artery 
luminal diameters were measured by an automated edge 
detection computer analysis ystem (Cardiovascular An- 
giography Analysis system, CAAS; Pie Data Medical, 
Neptune, N.J.). End-diastolic film frames were used for 
analysis, and specific segments of the IMA grafts were 
chosen. The size of the coronary catheter (8F in all cases) 
was used for calibration of the image in millimeters, and 
correction was made for radiographic pincushion distor- 
tion. In total 15 IMA segments were analyzed--seven 
pedicled and eight free IMA segments. Of the 15 films, 7 
were reanalyzed by a second observer, and the measure- 
ment was highly reproducible: r = 0.95 and p = not 
significant between observations. 
Data presentation. Diameters of the grafts are ex- 
pressed in millimeters or as percent diameter change from 
the control value. Mean _+ 1 standard error of the mean is 
given for each dose of substance P. Responses were 
compared by means of repeated measures analysis of 
variance. A p value of <0.05 was taken to indicate 
significance. 
Results 
All patients tolerated the study, and no compli- 
cations occurred. No patients had symptoms of 
angina, although mild left-sided chest discomfort 
was experienced by patients undergoing studies of 
the pedicled IMA graft at the time of contrast 
injection. This was not severe enough to terminate 
the study. 
Individual responses to substance P and isosor- 
bide dinitrate are shown in Table II. There was no 
significant effect of saline infusion on vessel diame- 
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Table I. Operative, angiographic, andclinical details of patients undergoing coronary angiography and bypass 
graft restudy with substance P infusion in free right and pedicled left IMA 
Date of 
Patient Age at CABG Patient 
No. Sex study (yr) operation Location fbypass grafts Complications Date of angiogram symptoms 
1 M 50 11/23/87 LIMA-LAD, FRIMA-D1, None 7/13/91 (All grafts None 
SVG-PDA, SVG-OM2 patent) 
2 M 41 7/1/87 LIMA-LAD, FRIMA- None 11/7/91 (All grafts None 
Ramus, SVG-RCA patent) 
3 M 49 9/11/89 LIMA-LAD, FRIMA- None 11/7/91 (All grafts None 
Ramus, SVG-PDA, patent; good 
SVG-OM1, SVG-OM2 LV) 
4 F 40 10/9/89 LIMA-LAD, FRIMA- None 9/14/91 (All grafts None 
OM1, SVG-RCA patent; good 
LV) 
5 M 46 9/21/90 LIMA-LAD, FRIMA- None 9/29/91 (All grafts None 
Ramus, SVG-RCA, patent; good 
SVG-D1 LV) 
6 M 57 9/7/90 LIMA-LAD, FRIMA- None 8/29/91 (Arterial None 
OM2, SVG-RCA, grafts patent; 
SVG-OM1 SVG to RCA 
occluded) 
7 M 58 11/8/91 LIMA-LAD, FRIMA- None 2/6/92 (SVG-OM2 None 
OM1, SVG-OM2, occluded; good 
SVG-PDA LV) 
8 M 48 10/23/91 LIMA-LAD, FRIMA-D1, None 2/22/92 (All grafts None 
FRIMA-OM1, SVG- patent) 
OM2, SVG-PDA 
9 M 55 12/18/85 LIMA-LAD, SVG-D1, None 3/12/92 (Occluded No symptoms 
SVG-Ramus, SVG- SVG-Ramus 
OM3, SVG-PDA and SVG-PDA) 
10 F 51 6/10/91 LIMA-LAD, SVG-OM1, None 2/6/92 (Occluded No symptoms 
SVG-RCA SVG-OM1) 
11 M 47 10/1/90 LIMA-LAD, SVG-OM1, None 2/26/92 (Patent No symptoms 
SVG-PDA grafts; good LV) 
12 M 71 10/3/90 LIMA-LAD, SVG-OM1, None 2/20/92 (Patent No symptoms 
SVG-PDA grafts; good LV) 
13 M 52 12/18/91 LIMA-LAD, SVG-RCA, None 2/22/92 (Occluded No symptoms 
SVG-OM2 graft to OM2) 
14 M 57 12/3/90 LIMA-LAD, SVG-D1, None 3/5/92 (Occluded No symptoms 
SVG-OM1, SVG-PDA SVG-OM1) 
15 M 40 2/2/92 LIMA-LAD, FRIMA- None 3/5/92 No symptoms 
OM1, SVG-RCA, 
SVG-PLV, RCA 
CABG, Coronary artery b pass grafting; LIMA, pedicled left internal m mmary artery; LAD, left anterior descending coronary artery; FRIMA, free right 
internal mammary artery; D1, first diagonal of LAD; SVG, saphenous vein graft; PDA,posterior descending artery; OM2, second obtuse marginal rtery; LV, 
left ventricle; OM1, first obtuse marginal artery; RCA, right coronary artery; OM3, third obtuse marginal artery; PLV, posterior left ventricular branch. 
ter. The mean dose response for pedicled and free 
IMA grafts are shown in Fig. 1. Maximal response to 
substance P at the highest dose used was 8.7% - 
1.8% in pedMed grafts compared with 8.8% _ 2.3% 
in free grafts (p = not significant). Infusion of 
isosorbide dinitrate produced only minimal further 
dilatation in both groups, and this effect was not 
significant. No significant difference was found be- 
tween the maximal responses of free and pedicled 
IMA vessels during all doses of the substance P 
infusion, and no difference was found in the re- 
sponse to isosorbide dinitrate. Fig. 2, A and B shows 
a typical response in a free IMA graft before 
substance P infusion and after infusion of the max- 
imal dose. Fig. 3, A and B similarly shows the 
appearance of the pedMed IMA in one of the 
patients before infusion of substance P and after 
infusion of the maximal dose. 
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Tab le  II. Absolute diameter and percent diameter change in free right IMA grafts and pedicled left IMA grafts 
Substance P dose Free right IMA Free right IMA Pedicled left IMA Pedicled left IMA 
Patient (pmol/min) diameter ( am) percent diameter change diameter (mm) percent diameter change 
1 Saline 2.63 0 
1.4 2.92 11.03 
2.8 3.09 17.49 
5.6 3.01 14.45 
11.2 3.23 22.81 
22.4 3.08 17.11 
ISDN 3.17 20.53 
2 Saline 2.89 0 
1.4 2.82 -2.42 
2.8 2.97 5.32 
5.6 
11.2 2.86 -1.04 
22.4 2.90 0.35 
ISDN 2.94 1.73 
3 Saline 2.71 0 
1.4 2.85 5.17 
2.8 2.85 5.17 
5.6 2.79 2.95 
11.2 2.82 4.06 
22.4 2.81 3.69 
ISDN 2.85 5.17 
4 Saline 2.51 0 
1.4 2.67 6.37 
2.8 2.73 8.76 
5.6 2.57 2.39 
11.2 2.62 4.38 
22.4 2.78 10.76 
ISDN 2.79 11.16 
5 Saline 2.49 0 
1.4 2.51 0.8 
2.8 2.56 2.81 
5.6 2.52 1.2 
11.2 2.63 5.62 
22.4 2.66 6.82 
ISDN 2.65 6.43 
6 Saline 2.63 0 
1.4 2.65 0.76 
2.8 2.68 1.9 
5.6 2.75 4.56 
11.2 2.78 5.7 
22.4 2.81 6.84 
ISDN 2.84 7.98 
7 Saline 2.27 0 
1.4 2.31 1.76 
2.8 2.54 11.89 
5.6 2.58 13.66 
11.2 2.69 18.5 
22.4 2.71 19.38 
ISDN 2.7 18.94 
8 Saline 2.75 0 
1.4 2.69 -2.18 
2.8 2.78 1.09 
5.6 2.81 2.18 
11.2 2.9 5.45 
22.4 2.91 5.82 
ISDN 2.91 5.82 
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Table II. Continued 
Substance P dose Free right IMA Free right IMA Pedicled left IMA Pedicled left IMA 
Patient (pmol/min) diameter (ram) percent diameter change diameter (ram) percent diameter change 
9 Saline 2.68 0 
1.4 2.61 -2.61 
2.8 2.77 3.36 
5.6 2.75 2.61 
11.2 2.72 1.49 
22.4 2.66 -0.75 
ISDN 2.84 5.97 
10 Saline 2.16 0 
1.4 2.15 -0.46 
2.8 2.21 2.31 
5.6 2.29 6.02 
11.2 2.27 5.09 
22.4 2.32 7.41 
ISDN 2.34 8.33 
11 Saline 2.56 0 
1.4 2.58 0.78 
2.8 2.69 5.08 
5.6 2.75 7.42 
11.2 2.78 8.59 
22.4 2.81 9.77 
ISDN 2.85 11.33 
12 Saline 2.45 0 
1.4 2.48 1.22 
2.8 2.59 5.71 
5.6 2.64 7.76 
11.2 2.76 12.65 
22.4 2.79 13.88 
ISDN 2.82 15.1 
13 Saline 2.59 0 
1.4 2.61 0.77 
2.8 2.72 5.02 
5.6 2.85 10.04 
11.2 2.89 11.58 
22.4 2.84 9.65 
ISDN 2.91 12.36 
14 Saline 2.32 0 
1.4 2.39 3.02 
2.8 2.35 1.29 
5.6 2.37 2.16 
11.2 2.48 6.9 
22.4 2.52 8.62 
ISDN 2.56 10.34 
15 Saline 2.67 0 
1.4 2.72 1.87 
2.8 2.79 4.49 
5.6 2.85 6.74 
11.2 2.92 9.36 
22.4 2.99 11.99 
ISDN 2.97 11.24 
ISDN, Isosorbide dinitrate. 
Discussion 
This study shows that the dilatory ability of free 
and pedicled IMA grafts, through endothelial-de- 
pendent and -independent mechanisms, is compara- 
ble early and late after coronary artery bypass 
surgery. The dilatory ability of the right IMA as a 
free graft appears not to be affected by transection 
of this vessel near its point of origin. Therefore 
denervation, as well as the loss of the vasa vasorum 
and lymphatics, does not significantly affect endo- 
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Fig. 1. Mean dose response to increasing doses of substance P infusion followed by isosorbide dinitrate (2 
mg over 2 minutes) in seven patients with pedicled left internal mammary artery grafts (Ped) and eight 
patients with free right internal mammary artery grafts (Free). ISDN, Isosorbide dinitrate. 
Fig. 2. A, Angiographic appearance of a free right internal mammary artery graft after control (saline 
0.9%) infusion and before substance P infusion. B, Angiographic appearance of free right internal 
mammary artery graft shown in Fig. 2 after infusion of substance P at maximal dose (22.4 pmol/min for 2 
minutes). Note apparent increase in diameter of vessel with vasodilatory effects of substance P on native 
circulation. 
thelial function of the free IMA graft. These find- 
ings have important implications in terms of graft 
survival and long-term results after coronary artery 
bypass surgery. 
Previous longitudinal studies have shown that the 
IMA graft has a substantially improved long-term 
patency when compared with saphenous vein 
grafts, 2 improves urvival, and is associated with a 
decreased frequency of other cardiac events. 1'22 
Morphologic studies have shown that although some 
fibrointimal proliferation does occur in IMA grafts 
atherosclerosis is extremely rare. 23 Although use of 
the IMA for coronary bypass surgery increases 
operative time, 24 it is unlikely that there is any 
increased surgical r i sky  The inevitable fate of 
venous bypass grafts appears to be the development 
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Fig. 3. A, Angiographic appearance ofa pedicled left internal mammary artery graft after control (saline 
0.9%11 infusion and before substance P infusion. B, Angiographic pearance of pedicled left internal 
mammary artery graft shown in A after infusion of substance P at maximal dose (22.4 pmol/min for 2 
minulLes). Note apparent increase in diameter of vessel with vasodilatory effects of substance P on native 
circulation. 
of atherosclerosis, severely limiting their long-term 
utility.26, 27 
Therefore, the finding that the free IMA func- 
tions in an almost identical manner to the pedicled 
IMA suggests that it too will have an increased 
survival when compared with venous grafts and that 
it should be used more frequently for the treatment 
of coronary artery disease. Bilateral use of the IMA 
has already been shown to have a low operative risk 
with excellent long-term functional improvement 
and survival s and may be particularly useful for 
myocardial revascularization i reoperations 28'29 
where survival and functional improvement may be 
comparable with those patients undergoing primary 
revascularizations with bilateral IMAs. The use of 
the right IlVlA as a pedicled graft may be more 
difficult because of inadequate l ngth often limiting 
its use to grafting the right coronary artery. 9 In 
addition, freeing this vessel of endothoracic fascia, 
internal mammary veins, and lymphatics--a tech- 
nique known as skeletonization3°--may provide 
greater length but still usually does not permit 
grafting of  the left anterior descending coronary 
artery or its branches. Use of the right IMA as a free 
graft allows it to be used for potentially greater 
numbers: of sites without he constraints of length if 
the vessel is pedicled. 
Arterial grafts provide an alternative to venous 
bypass grafting and attention has also recently fo- 
cused on the use of the gastroepiploic artery as an 
alternative arterial conduit. Endothelial function of 
this vessel has also been examined in vitro, and it has 
been shown that this vessel has a strong capacity to 
secrete endothelium-derived nitric oxide. 31 The L- 
arginine pathway in both vessels has been shown to 
be similar, although the gastroepiploic vessel may 
have a difference in prostaglandin metabolism com- 
pared with the IMA 32 and a greater capacity for 
vasodilatation. 33 Other arterial grafts which have 
recently been advocated include the inferior epigas- 
tric 34'35 and the radial artery. 36 However, it is 
probable that the IMA is more suited for use in 
coronary artery grafting because of its histologic 
structure 37 and the nature of its endothelial and 
smooth muscle function compared with other arter- 
ies which may be used for arterial grafts. 
Although the endothelial vasodilatory capacity of 
the IMA as shown in the present study does not 
appear to be as great as the native coronary circu- 
lation 16 or the gastroepiploic artery, 31 a recent study 
examining Doppler flow in response to various 
stimuli including exercise showed that the blood 
flow in this vessel increases appropriately. 38 In ad- 
dition an in vitro study in a canine IMA preparation 
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showed release of endothelium-derived r laxing fac- 
tor when the vessels were perfused with a physio- 
logic salt solution, 39 suggesting that flow mediated 
dilation of this vessel occurs in the setting of in- 
creased myocardial oxygen consumption. The gas- 
troepiploic artery showed a greater increase in flow 
on taking food. 38 Arterial grafts may be more phys- 
iologic for the treatment of coronary stenoses with a 
capacity for flow-dependent vasodilatation 11 and 
may therefore be able to respond appropriately to 
changes in myocardial oxygen consumption. Saphe- 
nous vein grafts, by comparison, probably only func- 
tion as conduits and have been shown, in vivo, to 
have a limited response to nitrate infusion 4° and are 
therefore unlikely to be able to exhibit flow-medi- 
ated changes in diameter. These factors may be of 
importance in ischemia of microvascular origin. 41 
Selective loss of acetylcholine-mediated r laxation 
in vein grafts has been observed in the early post- 
operative period and may have a role in eventual 
vein graft failureY 
It is possible that the observed effect on the 
vessels studied may not be a direct effect, but the 
result of flow-mediated ilatation ~1 as a result of 
increased blood flow caused by substance P in the 
distal coronary vascular bed. 16 If vessel dilatation 
occurred as a result of this effect, then it was 
observed in pedicled as well as free grafts suggesting 
that both function in a physiologic manner, with 
increases in flow causing an increase in diameter. 
This effect may be impaired in atherosclerosis 43 and 
because all patients underwent coronary bypass 
grafting for coronary artery disease, this mechanism 
of dilation may be impaired in both the groups 
studied. Nitrates are thought o have minimal effects 
on coronary blood flow and function as local smooth 
muscle vasodilators. 44 Because the infusion of 
isosorbide dinitrate did not cause further significant 
dilatation, it is most likely that the observed effect is 
a result of a local action of the substance P with 
maximal achievable dilatation due to this agent 
being observed. 
In conclusion, we have shown that the right IMA, 
used as a free graft for grafting any of the coronary 
arteries, functions in the same way as a pedicled left 
IMA. Endothelial-dependent and endothelial-in- 
dependent vasodilatory mechanisms are compara- 
ble in both types of graft and also suggest hat 
these grafts may function in a more physiologic 
manner than vein grafts. Use of longer lasting 
arterial grafts for coronary revascularization, in- 
cluding greater numbers of free grafts, will im- 
prove the long-term beneficial effects of this pro- 
cedure and prevent the need for reoperation 
because of venous graft failure, 45 which remains 
the main reason for symptomatic deterioration 
after bypass grafting. 
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